title: Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).
abstract: We retrospectively reviewed to investigate the efficacy and toxicity of monotherapy with S-1 in patients with advanced or recurrent gastric cancer after failure of first-line chemotherapy. Twenty-one patients were evaluated. The median number of treatment cycles was 2 (range 1-19). There were no cases showing either complete or partial response, and 10 patients (47.6%) showed stable disease. The median progression-free survival was 89 days. Sixteen patients (76%) received third-line chemotherapy. The median survival time was 271 days after the initiation of S-1, with a 1-year survival rate of 32%. Hematological toxicities were Grade 4 anemia (9.5%), Grade 3 or 4 neutropenia (9.5%) and leukopenia (4.7%). As for non-hematological toxicities, Grade 3 or 4 diarrhea and anorexia were noted in 9.5% and 14.2% of the patients, respectively. S-1 was found to show no efficacy and cannot be recommended for second-line chemotherapy against gastric cancer.
authors.affiliation: Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-Gun, Shizuoka, Japan. a.ono@scchr.jp
authors.forename: Akira
authors.initials: A
authors.lastname: Ono
authors.forename: Narikazu
authors.initials: N
authors.lastname: Boku
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Onozawa
authors.forename: Shuichi
authors.initials: S
authors.lastname: Hironaka
authors.forename: Akira
authors.initials: A
authors.lastname: Fukutomi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yasui
authors.forename: Kentaro
authors.initials: K
authors.lastname: Yamazaki
authors.forename: Takayuki
authors.initials: T
authors.lastname: Yoshino
authors.forename: Keisei
authors.initials: K
authors.lastname: Taku
authors.forename: Takashi
authors.initials: T
authors.lastname: Kojima